The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests
about
Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes?The application of biomarkers in clinical trials for motor neuron diseaseStatistical approaches for evaluating surrogate outcomes in clinical trials: A systematic review.SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis.Evidence-based mechanistic reasoning.
P2860
The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The true treatment benefit is ...... measured with diagnostic tests
@ast
The true treatment benefit is ...... measured with diagnostic tests
@en
type
label
The true treatment benefit is ...... measured with diagnostic tests
@ast
The true treatment benefit is ...... measured with diagnostic tests
@en
prefLabel
The true treatment benefit is ...... measured with diagnostic tests
@ast
The true treatment benefit is ...... measured with diagnostic tests
@en
P2093
P2860
P1476
The true treatment benefit is ...... measured with diagnostic tests
@en
P2093
Alain Leizorovicza
Behrouz Kassaï
Francois Gueyffier
Jean-Pierre Boissel
Michel Cucherat
Nirav R Shah
P2860
P304
P356
10.1016/J.JCLINEPI.2005.02.024
P577
2005-10-01T00:00:00Z